Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bristol-Myers Squibb 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Bristol-Myers Squibb 1Q

Biopharmaceutical sales totaled $4.3 billion in the quarter, with U.S. sales up 13% to $2.8 billion and International sales down 11% to $1.5 billion (+2% excluding foreign exchange impact).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 1Q

1Q Revenues: $5.0 billion (+3%)

1Q Earnings: $638 million (-3.5%)

Comments: Biopharmaceutical sales totaled $4.3 billion in the quarter, with U.S. sales up 13% to $2.8 billion and International sales down 11% to $1.5 billion (+2% excluding foreign exchange impact). Sales growth in the quarter was led by key drivers including Abilify, up 30% to $589 million, and Plavix, up 10% to $1.4 billion. Sales of Orencia grew 43% to $124 million and Sprycel sales were up 33% to $88 million. Reyataz sales were $322 million (+8%). Baraclude sales were $152 million (+41%). Erbitux sales were down 12% to $164 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters